Progress in #GenerativeBiology becomes real when a molecule performs exactly as it was designed. Today, we announced the initiation of SOLAIRIA, the first global Phase 3 studies of a long-acting anti-TSLP antibody for #SevereAsthma. These studies will evaluate GB-0895, which blocks TSLP — an upstream driver of the inflammatory response in #asthma. Using our generative optimization technology stack, GB-0895 was computationally designed to improve potency and half-life while retaining specificity, supporting a potential every-six-month dosing schedule. This move into #Phase3 demonstrates what programmable biology can enable — design translating into development. Learn more about SOLAIRIA → https://lnkd.in/eMTCZpXC Read our full announcement → https://lnkd.in/e2Q9K7-Y #ClinicalTrials | #RespiratoryHealth
Exciting progress!
Congrats on reaching Phase 3! This is a great example of how programmable biology can translate cutting-edge design into real-world patient impact.